Welcome to our dedicated page for GWPH news (Ticker: GWPH), a resource for investors and traders seeking the latest updates and insights on GWPH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GWPH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GWPH's position in the market.
GW Pharmaceuticals announced that CEO Justin Gover will present a business update and 2021 outlook at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 10:00 am PT (1:00 pm ET). A Q&A session will follow at 10:20 am PT (1:20 pm ET). Investors can access a live audio webcast through GW's corporate website. GW Pharmaceuticals focuses on cannabinoid prescription medicines, with its lead product, EPIDIOLEX, approved for treating seizures associated with specific syndromes.
GW Pharmaceuticals announced positive results from a Phase 3 clinical trial of EPIDIOLEX® (cannabidiol) for treating seizures linked to tuberous sclerosis complex (TSC). The study revealed a significant seizure reduction of 48.6% and 47.5% for two dosing regimens compared to 26.5% in the placebo group (p<0.001). The trial included 224 patients aged 1 to 65 and lasted 16 weeks. Notably, safety profiles remained consistent with earlier studies. Results were published in JAMA Neurology, reinforcing EPIDIOLEX's efficacy as a new option for treatment-resistant seizures.
GW Pharmaceuticals announced its participation in the Needham Virtual Epilepsy & Pain Conference on December 10, 2020, at 11:00 AM EST. The presentation will focus on their advancements in cannabinoid prescription medicines.
A live audio webcast can be accessed via GW's corporate website. The company is known for its EPIDIOLEX product, which treats seizures linked to conditions like Lennox-Gastaut syndrome and Dravet syndrome in patients aged one and older.
GW Pharmaceuticals plc announced the presentation of long-term data on EPIDIOLEX (cannabidiol) at the upcoming American Epilepsy Society (AES) Annual Meeting from December 4-8, 2020. This data will focus on the treatment of tuberous sclerosis complex (TSC) and various seizure subtypes. The newly available data highlights more than three years of patient outcomes, emphasizing the drug's efficacy and safety in treating treatment-resistant epilepsy in TSC patients. The presentation aims to address the high demand for effective treatment options in this population.
GW Pharmaceuticals will present at the Evercore ISI HealthCONx Conference on December 2, 2020, at 1:50 pm EST. The event highlights the company's commitment to cannabinoid prescription medicines. A live audio webcast will be accessible via GW's corporate website. The company is known for its lead product, EPIDIOLEX, used for treating seizures linked to Lennox-Gastaut syndrome and other conditions. GW has numerous cannabinoid candidates in late-stage clinical trials aimed at FDA approval for various medical applications.
GW Pharmaceuticals has revealed positive results from an analysis of three Phase 3 clinical trials of nabiximols targeting spasticity in multiple sclerosis (MS). The studies demonstrated statistically significant improvements in spasticity without causing increased muscle weakness or impacting walking speed. Data was derived from 531 participants across trials GWMS0106, GWSP0604, and SAVANT. Nabiximols is currently in Phase 3 development in the U.S. for MS spasticity, with plans for additional global trials.
GW Pharmaceuticals will present at the Stifel Virtual Healthcare Conference on November 18, 2020, at 1:20 pm EST. A live audio webcast will be accessible from their corporate website, with a replay available post-event. Renowned for its cannabinoid medicines, GW's lead product, EPIDIOLEX, is FDA-approved for treating seizures linked to Lennox-Gastaut syndrome and other conditions. The company is advancing multiple clinical programs, including treatments for multiple sclerosis and autism.
GW Pharmaceuticals announced a significant revenue growth of 51% in Q3 2020, totaling $137.1 million, up from $91 million in Q3 2019. The company attributes this success to the launch of Epidiolex for treating seizures associated with Tuberous Sclerosis Complex (TSC). The net loss reduced to $12.2 million from $13.8 million year-over-year. The company is actively progressing clinical trials, including a Phase 3 program for nabiximols in multiple sclerosis spasticity.
GW Pharmaceuticals plc has announced the initiation of a U.S. Phase 3 clinical trial for nabiximols, aimed at treating multiple sclerosis (MS)-associated spasticity. This follows positive outcomes from prior European trials, which highlighted its safety and efficacy. With five pivotal studies planned, GW anticipates filing for New Drug Application (NDA) as early as mid-next year if results are favorable. The trial will enroll 446 participants over 12 weeks and address the significant need for effective MS treatments in the U.S., considering many patients currently self-medicate with unapproved products.
